Clinical trial results published in the New England Journal of Medicine show that tirzepatide, the active ingredient in the brand-name medications Mounjaro and Zepbound, helps patients lose an average of 50 pounds (22.8 kilograms) over 72 weeks. Funded by drug manufacturer Lilly, the study provides a direct comparison between leading obesity treatments and establishes new performance benchmarks for non-surgical weight management options.
Clinical Trial Design and Weight Loss Outcomes
The research evaluated 751 adult participants in the United States who were classified as overweight or obese and had at least one weight-related health complication, excluding diabetes. According to the study data, participants receiving weekly injections of tirzepatide at the highest tolerated doses of 10 milligrams or 15 milligrams shed an average of 50 pounds, or 22.8 kilograms, over the 72-week trial period.
By comparison, participants taking semaglutide—marketed as Wegovy—at doses of 1.7 milligrams or 2.4 milligrams lost an average of 33 pounds, or 15 kilograms.
Regulatory Status and Clinical Indications
Tirzepatide is a weekly subcutaneous injection that functions by targeting hunger hormones to suppress appetite and regulate blood glucose levels. Initially authorized to manage blood sugar in patients with type 2 diabetes under the brand name Mounjaro, the medication is also marketed under the brand name Zepbound specifically for chronic weight management.
Regulatory approvals generally authorize these medications for individuals with a body mass index (BMI) of 30 or higher, or a BMI of 27 to 30 accompanied by at least one weight-related comorbidity such as hypertension, dyslipidemia, or cardiovascular disease.
Comparative Efficacy in Obesity Medicine
The landscape of obesity pharmacotherapy has evolved through successive generations of injectable treatments. Earlier options, such as liraglutide sold under the brand name Saxenda, required daily administration and clinical trials indicated that approximately 56 percent of patients achieved a 10 percent reduction in body weight.
The introduction of once-weekly semaglutide formulations raised clinical expectations, demonstrating average weight losses of up to 15 percent over 18 months. The latest head-to-head study of its kind shows that tirzepatide achieves average reductions exceeding one-fifth of initial body weight, with select participants achieving losses approaching a quarter of their starting mass.
Keep reading